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The INK4a gene, one of the most frequently disrupted loci in human cancer, encodes two unrelated proteins, p16
INK4a and p19
ARF
, that both block cell proliferation. p16
INK4a is a component of the Rb regulatory pathway, while p19 ARF has been functionally related to p53. Moreover, p16 INK4a is inactivated in many human tumors, while it has been very recently reported that p19 ARF null mice develop tumors early in life. We show here that p19 ARF is able to inhibit the formation of G418-resistant colonies when transfected into human and mouse cell lines expressing wild-type p53, regardless of p16 status. Moreover its amino terminal domain encoded by exon 1b is still sucient to obtain the same eect. We have analysed the ability of p19 ARF to interfere with Rasmediated cellular transformation in the NIH3T3 cell line. Cotransfection of p19 ARF together with activated ras potently inhibited the formation of transformed foci in a dose-dependent manner. We have also isolated stable NIH3T3 transfectants expressing p19 ARF and we have measured their growth properties as well as their eciency of transformation by activated ras. Our results suggest that p19 ARF can interfere with oncogene-mediated transformation, without signi®cantly aecting NIH3T3 cell growth, at least at the levels of expression achieved in these experiments.
Keywords: cellular transformation; tumor suppressor genes; cell cycle regulation; INK4a locus Inactivation of the INK4a locus on human chromosome 9p21 by point mutation or deletion is observed in many cancers, including familiar melanomas and a wide variety of sporadic tumors of both childrens and adults (CalabroÁ et al., 1996; Kamb et al., 1994a,b; Okamoto et al., 1994 ). An increasing number of evidence now suggests that the frequency of involvement of the INK4a locus in human cancers may be second only to that of p53, underscoring its broad importance as a tumor suppressor gene. The INK4a locus encodes the cyclin D-dependent kinase inhibitor p16
INK4a whose expression in mammalian cells can induce G1 phase arrest (Sherr and Roberts, 1995) . p16
INK4
, inhibiting the activities of the cyclin Ddependent kinases, cdk4 and cdk6, prevents phosphorylation of the retinoblastoma protein (pRB).
A surprising feature of the INK4a locus is that it encodes a second, entirely unrelated protein, p19 ARF (p19 Alternative Reading Frame) (Mao et al., 1995; Quelle et al., 1997; Stone et al., 1995) . The locus has the capacity to give rise to two distinct transcripts from dierent promoters. Each transcript has a speci®c 5' exon, E1a or E1b (the 1b exon is approximately 15 kb upstream from exon 1a), which is spliced into common exons E2 and E3. The E1a-containing transcript encodes p16
INK4a and the E1b-containing transcript encodes p19 ARF from a dierent reading frame initiated in the E1b exon. Strikingly p19 ARF , like p16
INK4a
, is able to induce growth arrest in mammalian ®broblasts (Quelle et al., 1995) .
The presence of overlapping frames of the two INK4a genes raises the question of the eect of mutations in exon 2 on both proteins. Recently it has been shown that some of these mutations inactivate p16
, but do not aect functionally p19 ARF . Moreover, the unique amino terminal domain encoded by exon 1b was shown to be both necessary and sucient for inducing G1 arrest in mice. Therefore, it is likely that the numerous cancerassociated mutations within exon 2 speci®cally target p16
. Nevertheless tumor-associated deletions in chromosome 9p21 often encompass both exon 1a and 1b, as well as the adjacent p15
INK4b gene (Stone et al., 1995) , also coding for a CDK-inhibitor. It has been reported that p19 ARF null mice develop tumors early in life (Kamijo et al., 1997) , suggesting that ARF, like INK4a is also a bona ®de tumor suppressor. Moreover, embryonic ®broblasts derived from p19 ARF null mice failed to undergo crisis after multiple passages in vitro and were eciently transformed by Ha-ras. Furthermore, MEFs derived from p19 ARF heterozygotes lost the remaining wild-type allele as they passed through crisis, supporting the importance of homozygous loss of p19 ARF in cellular immortalization. p19 ARF ectopic expression causes cell cycle arrest only in MEFs containing wild-type p53 (Kamijo et al., 1997) and a molecular mechanism explaining this observation has been recently proposed. It has been shown that p19 ARF can stabilize the p53 protein by binding to and promoting the degradation of MDM2 (Kamijo et al., 1998; Pomerantz et al., 1998; Zhang et al., 1998) . The critical role served by p53 in the control of both the cell cycle and the apoptotic pathway requires that p53 activity has to be subjected to multilevel regulation. One crucial level of regulation involves mdm2 (Haupt et al., 1997; Kubbutat et al., 1997) , a proto-oncogene that is ampli®ed in 30 ± 40% of sarcomas (Oliner et al., 1992) , encoding a protein that regulates the level of p53, inducing its degradation.
The unusual high rate of INK4a gene deletions in human cancer can now be explained by its unusual genomic organization, as the two products of this locus, p16
INK4a and p19 ARF , relate to the two central growth control pathways, Rb and p53, respectively.
Very few data exist on the eects of the human p19 ARF in cell cycle control (Arap et al., 1997; Ligget et al., 1996) . In this paper we have investigated the ability of the entire human p19 ARF and of its amino terminal domain encoded by exon 1b to inhibit the formation of G418-resistant colonies when transfected into human and mouse cell lines diering in the status of p53 and p16
INK4a genes and to interfere with Ras-mediated cellular transformation in the NIH3T3 cell line.
The p19 ARF cDNA has been isolated by RT ± PCR from Hela cells and cloned into an eukaryotic expression vector that contains a CMV promoter and antibiotic resistance to G418 (p19). To determine which region of p19 ARF is responsible for inhibiting the colony formation, two additional vectors, expressing the N-terminal and the C-terminal portion of the protein respectively, were constructed. The ®rst contains only sequences spanning the exon 1b (Np19), while the second (C-p19) contains the cDNA from a natural mutant of p16
INK4a isolated by us from a thyroid cancer cell line (TPC1) (CalabroÁ et al., 1996) . TPC1 cDNA bears a frameshift mutation in exon 2, so that it encodes a chimeric protein made of p16 INK4a -exon 1a and p19 ARF -exon 2 derived portions. Transcription and translation in vitro of the three cDNAs con®rmed that p19, N-p19 and C-p19 encode polypeptides of the expected sizes (Figure 1) . A fourth vector containing the p16
INK4a full-length cDNA from Hela cells was also constructed, to be used as control (Spillare et al., 1996) .
Human and mouse cell lines diering in the status of p53 were used as recipient for gene transfer. Hela cell line expresses p53 that is inactivated by the viral protein E6 (Ligget et al., 1996) and Saos 2 cells are p53 null (Pomerantz et al., 1998) , while U-2OS cells and NIH3T3 express a wild-type p53. Moreover NIH3T3 cell line bears a deletion of the INK4a locus. We transfected each construct into all four cell lines. After completion of drug selection, growth suppression was quanti®ed by comparing the relative number of drug resistant colonies obtained with each construct to that obtained with the empty vector. Figure 2 shows that transfection of the entire p19 ARF strongly inhibits the G-418 R colony formation only in U-2OS and NIH3T3 cell lines. Moreover, the results clearly show that the N-terminal domain retains almost full activity in the U-2OS cell line and reduces the number of colonies up to 70% with respect to the control in NIH3T3 cells, while C-p19, expressing the p19 ARF C-terminal domain, does not signi®cantly inhibit colony formation. The lower eciency of the human amino terminal domain in inhibiting cell cycle progression in the NIH3T3 cell line could re¯ect some dierences in the activity of mouse and human p19 ARF proteins. Mouse and human ARF polypeptides are 45% identical through their exon 1b segments and 50% identical overall. By comparison, mouse and human p16 INK4a exon 1a segments are 72% identical, and the p16
INK4a proteins share 65% identity overall (Quelle et al., 1995) .
The lack of growth suppressive eects in Hela cells, in which p53 is inactivated by E6 papillomavirus protein, is apparently in contrast with another report (Ligget et al., 1996) , showing that transfection of p19 ARF causes a 20 ± 25% decrease in survival of Hela cells and cell cycle arrest in G 0 -G 1 . The dierent experimental approach used by us could be a possible explanation for the apparent discrepancy.
To analyse the ability of p19 ARF to interfere with rasmediated cellular transformation, NIH3T3 cells were cotransfected with an expression vector containing an activated ras ), together with one of the three forms of the p19-expression vectors, (p19, N-p19, C-p19). Cotransfections of ras and either the empty vector or the p16 expression vector were performed as negative and positive controls respectively. Transformation was quantitated by counting the number of transformant foci that could be detected two weeks following transfection. As shown in Figure  3 , p19 ARF expression potently inhibited the formation of Ras-induced foci and the inhibitory eect was similar to that displayed by p16 (Serrano et al., 1995) (Figure 3a and b) . The ability to inhibit foci formation Figure 1 In vitro transcription, translation. Coupled in vitro transcription and translation reactions were performed using the Linked SP6/T7-TNT kit following the manifacturer's instructions (Boehringer Mannheim). Proteins were electrophoresed on a 14% sodium dodecyl sulphate-polyacrylamide gel. The gel was ®xed, dried and exposed to X-ray ®lm. Expression plasmids were constructed as follows: the full length human ARF coding sequence was ampli®ed from Hela RNA by RT ± PCR using the sense primer LA40 (5'-TCGAAGCTTGAGGCGGCGAGAA-CATGG-3') and the antisense LA10 (5'-GCTCTAGAT-CAATCGGGGATGTCTGAGGGA-3'). Exon 1 b of human p19 ARF was ampli®ed from genomic DNA by PCR using the sense primer LA40 and the antisense 3'exlb (5'-TTCGAATTCCT-TACCTACCTGGTC-3'). The p16
INK4a mutant cDNA was ampli®ed from TPC-1 cell line RNA by RT ± PCR using the sense primer p16H5' (5'-AATAAGCTTATGGAGCCGGCGGC-GGGGAGCAG-3') and the antisense p16X3' (5'-GCTCTAGAT-CAATCGGGGATGTCTGAGGGAC-3'). All products were cloned in the pRc-CMV vector is retained by p19 ARF amino terminal domain, although at a lower eciency, while C-p19 is fully inactive. Cotransfection of ras with increasing amount of either p19 or N-p19 yielded progressively fewer transformed foci, suggesting that p19 ARF inhibits focus formation in a dose-dependent manner (Figure 3c) .
While the results of these experiments suggest that forced p19 ARF overexpression elicits an inhibitory eect on the growth of transformed cells, they do not clarify whether this eect is due to a generalized cell cycle arrest or to a more speci®c interference in the ras transformation pathway. To address this point we have isolated NIH3T3 clones stably expressing p19 ARF and we have measured the levels of p19 ARF expression, their growth properties, as well as their eciency of transformation by activated ras. NIH3T3 cells were transfected with either the expression vector p19, or the empty vector. To allow detection of the protein in the transfected cells, the HA epitope tag (Hemagglutinine antigen) was fused to the N-terminus of p19. After drug selection several resistant clones were isolated and expanded (3T3-p19 clones and 3T3-neo clones). As shown in Figure 4 , ®ve of the 3T3-p19 clones were analysed by protein immunoblotting and expression of a similar level of HA-p19 ARF was observed in each ( Figure 4a ). The growth characteristics of the 3T3-neo and 3T3-p19 cell lines were analysed by measuring their doubling time in culture. As shown in Figure 4b only a slight dierence in growth rate could be detected between two dierent 3T3-p19 clones and the 3T3-neo cell line, and similar results were obtained for the other stable clones (data not shown). Moreover, a comparable saturation density was reached by all the clones.
Since the basic growth characteristics of the 3T3-p19 clones are not aected by the level of p19 ARF ectopic expression which was reached, these cells oer a suitable experimental system to analyse the eect of p19 ARF expression on the eciency of transformation b a % of colonies Figure 2 Colony-forming eciency assay. (a) Saos 2, U-2OS and Hela cell lines were maintained in DMEM medium supplemented with 10% foetal bovine serum, whereas NIH3T3 cells were maintained in DMEM supplemented with 10% calf serum. Cells were seeded into 6-well multiplates at densities that resulted in at least 50% con¯uence after 24 h and transfected with 2 mg of the individual plasmid DNAs by using the standard calcium phosphate method. Forty-eight hours after transfection the cells were replated in a 100 mm dish (Hela cells were replated in two 100 mm dishes), and selected with the appropriate concentration of G418 for 2 weeks. Saos 2, Hela and NIH3T3 cells were selected with 1 mg/ml and U-2OS cells with 600 mg/ml Geneticin (G418; Gibco/ BRL), respectively. After selection, the cells were ®xed and stained with crystal violet and the colonies were counted. The graphic represents the percentage of colonies obtained with the indicated plasmids relative to that detected on the pRc-CMV transfected plates. Values represent the mean of four independent experiments. Standard deviation for each value is also given. The full length human p16 INK4a coding sequence was ampli®ed from Hela RNA by RT ± PCR using the sense primer p16H5' and the antisense p16X3' primer. The obtained product was cloned in the pRc-CMV vector. (b) Representative plates from an experiment performed on U-2OS cells are shown by activated ras. The 3T3-p19 clones and the 3T3-neo clone were therefore transfected with ras and the number of transformed foci was quantitated two weeks after transfection. As shown in Figure 4c the eciency of transformation by ras is strongly reduced in all of the 3T3-p19 cell lines, compared to that obtained in the 3T3-neo control cell line, and the level of inhibition in some clones is as high as 85%. Moreover, after additional 7 day post-transfections, no signi®cant increase in the number of foci was observed (data not shown).
Compelling support for p16 INK4a as a critical target of tumorigenesis includes germline mutations/deletions exclusively aecting the p16
INK4a ORF in melanomaprone kindreds. With regard to p19 ARF , although direct evidence linking loss of p19 ARF function with human tumorigenesis has been lacking, many INK4a mutations/deletions map to the exon 2 region that is shared by p19 ARF and a p19 ARF speci®c knockout leads to spontaneous tumor formation in mice (Kamijo et al., 1997) . Moreover, the antioncogenic potency of p19 ARF has been recently tested in rat embryo ®broblasts cotransformation assays, against various oncogene combinations (Zhang et al., 1998) . The results clearly show that p19 ARF suppressed foci formation induced by either c-myc/Ras or E1a/Ras combinations, but not by T-Ag/Ras, suggesting that p19 ARF acts by inhibiting cellular transformation in a p53-dependent way.
Our results indicate that p19 ARF can speci®cally inhibit ras-mediated transformation without interfering with normal cell proliferation, at least in our experimental system and at the level of protein expression achieved. Possibly, the levels of ectopic p19 ARF achieved in these cells were below a threshold that would detrimentally aect normal growth. However, the achieved levels of p19 ARF expression eciently suppressed ras-mediated transformation, suggesting that the amount of p19 ARF expression required to inhibit transformation may be lower than that needed to aect normal cell cycle progression.
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